EMA Releases Pharmacogenomics Concept Paper - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Releases Pharmacogenomics Concept Paper


ePT--the Electronic Newsletter of Pharmaceutical Technology

The EMA has released a concept paper for a guideline on pharmacogenomic methodologies in the evaluation of authorized medicines to address the fact that genetic differences can cause variability in drug-therapy efficacy and safety. The limited scope of clinical trials means that rare but serious adverse drug reactions (ADRs) may not be discovered until after increased population exposure post authorization.

Included in the topics proposed for the guideline are the following:

  • Systematic consideration of pharmacogenomic effects and the implications of genomic biomarkers in terms of efficacy, effectiveness, and safety
  • Early consideration of when post authorization genomic data should be monitored and collected to confirm appropriate dose or comedication
  • Collection of genomic material during clinical trials and in the case of serious ADRs, lack of effectiveness or worsening of the condition
  • Methodologies for post authorization safety studies, and post authorization efficacy and effectiveness studies
  • Consideration of the level and type of evidence for identification of signals and how to report to the competent authorities
  • Risk-minimization measures (depending on the importance of possible clinical implications)
  • Labeling issues, including what pharmacogenomic information to include in the product information.

The EMA press release stated, “Identifying individuals at risk of side effects, unexpected complications or lack of efficacy may help the development of strategies to optimize the use of medicines.” The concept paper is open for public consultation until Mar. 15, 2012.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here